| P50 | author | Jean Schoenen | Q3174588 |
| | Arnaud Fumal | Q127389194 |
| P2093 | author name string | Jean Schoenen | |
| P2860 | cites work | Recent advances in the diagnosis and management of migraine | Q24535949 |
| | Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology | Q28138991 |
| | Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks | Q28171147 |
| | Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study | Q28182838 |
| | Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study | Q28196594 |
| | EFNS guideline on the drug treatment of migraine - report of an EFNS task force | Q28219436 |
| | Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature | Q28242073 |
| | Suppression of cortical spreading depression in migraine prophylaxis | Q28294907 |
| | Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study | Q28345604 |
| | Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study | Q28370593 |
| | Ergotamine in the acute treatment of migraine: a review and European consensus | Q28378061 |
| | Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs | Q57945428 |
| | Familial risk of migraine: A population-based study | Q61046096 |
| | Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society | Q70213757 |
| | Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study | Q71498689 |
| | Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test | Q72376056 |
| | Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs | Q72674958 |
| | Comorbidity of migraine and depression: investigating potential etiology and prognosis | Q73299949 |
| | Lamotrigine versus placebo in the prophylaxis of migraine with and without aura | Q73311988 |
| | Guidelines for controlled trials of drugs in migraine: second edition | Q73417055 |
| | Vagal nerve stimulation aborts migraine in patient with intractable epilepsy | Q74497867 |
| | Epidemiology of headache | Q74608181 |
| | Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMA | Q78129222 |
| | Psychological treatment of recurrent headache in children and adolescents--a meta-analysis | Q79371906 |
| | The prevalence of migraine and tension-type headaches among adolescents in Norway. The Nord-Trøndelag Health Study (Head-HUNT-Youth), a large population-based epidemiological study | Q79958709 |
| | Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study | Q79982530 |
| | [Patent foramen ovale and migraine, a fortuitus association or a causal relationship?] | Q80115974 |
| | Migraine-related vertigo: diagnosis and treatment | Q80340648 |
| | Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial | Q81248679 |
| | Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches | Q81294228 |
| | Cost of migraine and other headaches in Europe | Q81722442 |
| | Comparison of pre-headache phases and trigger factors of migraine and episodic tension-type headache: do they share similar clinical pathophysiology? | Q81775267 |
| | Does earlier headache response equate to earlier return to functioning in patients suffering from migraine? | Q82925546 |
| | Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. | Q55041322 |
| | Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. | Q55066560 |
| | Effectiveness and Tolerability of Acupuncture Compared With Metoprolol in Migraine Prophylaxis | Q56980880 |
| | Nitric oxide synthase inhibition in migraine | Q57024918 |
| | The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. | Q36771308 |
| | Menstrual migraine: a clinical review | Q36771978 |
| | Migraine in pregnancy and lactation: a clinical review | Q36779783 |
| | Management of medication-overuse headache | Q36941902 |
| | Genes, proteases, cortical spreading depression and migraine: impact on pathophysiology and treatment. | Q36966194 |
| | Emerging therapies for migraine | Q36992954 |
| | Tension-type headache: current research and clinical management | Q37037946 |
| | Migraine aura and related phenomena: beyond scotomata and scintillations | Q37142153 |
| | Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia | Q39316816 |
| | Traditional acupuncture in migraine: a controlled, randomized study | Q39330387 |
| | Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial | Q39391120 |
| | Determinants of patient satisfaction with migraine therapy | Q39424833 |
| | A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents | Q39425187 |
| | A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine | Q39427385 |
| | Naproxen sodium in the treatment of premenstrual symptoms. A placebo-controlled study | Q39528369 |
| | Patients' preference for migraine preventive therapy | Q40221803 |
| | The Mode of Action of Sumatriptan is Vascular? A Debate | Q40494636 |
| | Healthcare resource use and costs associated with migraine in a managed healthcare setting | Q40693759 |
| | Amitriptyline in the treatment of primary headaches | Q43265634 |
| | Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. | Q43551354 |
| | Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache | Q43923427 |
| | Migraine prevalence, disease burden, and the need for preventive therapy | Q43983035 |
| | Prednisolone does not reduce withdrawal headache: a randomized, double-blind study | Q44352981 |
| | A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache | Q44629636 |
| | A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine | Q44995793 |
| | Prevalence and impact of migraine and probable migraine in a health plan | Q46326510 |
| | Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial | Q46442389 |
| | Update on the prophylaxis of migraine | Q46714902 |
| | Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? | Q46808862 |
| | Prednisone vs. placebo in withdrawal therapy following medication overuse headache | Q46881702 |
| | Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients | Q48222453 |
| | Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study | Q48240550 |
| | Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: therapeutic potential for migraine | Q48291177 |
| | The pathophysiology of migraine: a review based on the literature and on personal contributions. | Q48471049 |
| | Prednisone as initial treatment of analgesic-induced daily headache | Q48715256 |
| | Neuromuscular transmission in migraine: a single-fiber EMG study in clinical subgroups | Q48903444 |
| | Subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements | Q49039497 |
| | Burden of migraine in the United States: disability and economic costs. | Q50644584 |
| | Repetitive intravenous dihydroergotamine as therapy for intractable migraine. | Q51807318 |
| | Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). | Q51919506 |
| | Healthcare resource and lost labour costs of migraine headache in the US. | Q53394535 |
| | A population-based analysis of the diagnostic criteria of the International Headache Society. | Q53399156 |
| | Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. | Q53699726 |
| | Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. | Q54033875 |
| | Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. | Q55040377 |
| | ??? | Q28191873 |
| | The International Classification of Headache Disorders: 2nd edition | Q29547231 |
| | Prevalence and burden of migraine in the United States: data from the American Migraine Study II. | Q31974113 |
| | Efficacy of biofeedback for migraine: a meta-analysis | Q33262687 |
| | Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. | Q33984103 |
| | Drug treatment of migraine in children: a comparative review | Q33999244 |
| | A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches | Q34003508 |
| | Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial | Q34099102 |
| | Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial | Q34167309 |
| | Prevention of menstrual migraine by percutaneous oestradiol | Q34290661 |
| | Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine | Q34304867 |
| | LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. | Q34326873 |
| | Petasites hybridus root (butterbur) is an effective preventive treatment for migraine | Q34380322 |
| | Acupuncture for patients with migraine: a randomized controlled trial | Q34415925 |
| | The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache | Q34420699 |
| | Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial | Q34458351 |
| | Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial | Q34503130 |
| | Migraine--current understanding and treatment | Q34504002 |
| | New appendix criteria open for a broader concept of chronic migraine | Q34523930 |
| | The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. | Q34536700 |
| | Recent advances in understanding migraine mechanisms, molecules and therapeutics | Q34586517 |
| | The global burden of headache: a documentation of headache prevalence and disability worldwide | Q34611721 |
| | Sumatriptan-naproxen for acute treatment of migraine: a randomized trial | Q34615293 |
| | Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials | Q34647375 |
| | The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria | Q34649337 |
| | The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients | Q34652827 |
| | Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine | Q34698074 |
| | Epidemiology and comorbidity of headache | Q34761503 |
| | Acute treatment and prevention of menstrually related migraine headache: evidence-based review | Q34772420 |
| | Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura | Q35485546 |
| | Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine | Q35775292 |
| | Cost of disorders of the brain in Europe | Q36118614 |
| | Migraine genetics: an update | Q36133899 |
| | The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). | Q36261290 |
| | Migraine preventive therapy: selection of appropriate patients and general principles of management. | Q36558665 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | migraine | Q133823 |
| P304 | page(s) | 1043-1057 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Neuropsychiatric Disease and Treatment | Q15716332 |
| P1476 | title | Current migraine management - patient acceptability and future approaches | |
| P478 | volume | 4 | |